Science

Apr 27, 2025, 09:05

Myeloma Paper of the Day, April 27th, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Elotuzumab with IMiDs and dex for relapsed/refractory AL amyloidosis shows hematologic response by 3 months in 32%; 4/33 had organ responses; median OS was 37 months and EFS was 11 months.”

“Elotuzumab in Combination With Dose Reduced IMiDs and Dexamethasone for AL Amyloidosis Patients With Relapsed/Refractory Plasma Cell Dyscrasia and Advanced Organ Involvement”

Authors: Tobias Dittrich, Timon Hansen, Christoph Kimmich, Kaya Veelken, Anna Jauch, Marc Raab, Carsten Müller-Tidow, Ute Hegenbart, Stefan Schönland.

More posts featuring Robert Orlowski.

amyloidosis Anna Jauch cancer Carsten Müller-Tidow Christoph Kimmich elotuzumab IMiDs Kaya Veelken Marc Raab Myeloma Paper of the Day OncoDaily Oncology relapsed/refractory AL amyloidosis Robert Orlowski Stefan Schönland Timon Hansen Tobias Dittrich Ute Hegenbart

10 Caring Notes from Pope Francis on Healthcare

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma